Video: 10 Minute IT Jams – A glimpse inside a ransomware cell
Techday's 10 Minute IT Jams provide sharp, to-the-point insights into emerging and established technology companies that operate in the Asia-Pacific region.
This is our fourth IT Jam with SonicWall, the cybersecurity company specialising in firewall, network security, cloud security and more.
It's also our second IT Jam with SonicWall senior manager of product marketing Brook Chelmo, and in this video Brook walks us through his one-on-one experience with a member of a ransomware cell, and why he had to throw all his previous misconceptions out the window.
Watch the video below.
APAC secure content management market to hit $2.2 billion by 2024
Check Point uncovers live Linux attack, urges users to take action
Sophos named a Numbering Authority in CVE programme
IronNet expands Asia Pacific presence with new strategic partnership
Sophos Rapid Response puts out the ransomware fire
Demystifying 'zero trust' and its role in cybersecurity
Quantea and Attivo Networks launch joint network security solution
"Attivo and Quantea together provide advanced, real-time, in-network threat detection and improved incident response."
SASE vs zero trust – or the best of both worlds
Zero trust and SASE work together by converging a least-privilege access strategy with an architecture that simplifies how highly distributed users, BYOD, and cloud resources are secured.
Hackers in your bedroom: Hackers targeting smart sex toys
A group of researchers reported vulnerabilities in an internet-enabled male chastity cage.
APAC secure content management market to hit $2.2 billion by 2024
The proliferation of cloud-based deployments will largely drive this, the report says, as the COVID-19 pandemic motivates more enterprises to move their workloads to the cloud and rely more on the internet.
Gartner names Zscaler the only leader in Magic Quadrant for Secure Web Gateways
"Legacy technology is an inhibitor to digital transformation."
Cybercriminals target COVID-19 vaccine - report
Attackers did not spare clinics where COVID-19 patients were being treated or pharmaceutical sites where vaccine research was being conducted.
